Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab and Bortezomib in Refractory KRAS Wild-Type Colorectal Cancer
NCT01504477Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Dec 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in colorectal cancer (CRC), sponsored by Georgetown University. Started Dec 2011; status: terminated.
02
Drugs
bortezomib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01504477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01504477.